Caribou Biosciences, Inc., one of a handful of biotechs working on therapies based around gene editing, is at a pivotal point as it gears up for clinical trials of its CRISPR-based technology.
While the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm has announced that it is licensing back two gene editing compounds that can
Shares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the CEO of one of the leading biotechs in the field, Editas.
Going into 2018 you might have expected this to be the year of Alzheimer’s drugs, with several promising trials underway – but unfortunately the last 12 months have been marked by failure a
AstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling and big data processing that will develop CRISPR technology to b
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
